Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: Gerresheimer AG
/ Key word(s): Miscellaneous
Duesseldorf/Kosamba, May 16, 2022. Gerresheimer has significantly ramped up its glass and plastic production capacities in India to satisfy its global pharma customer needs. A new modern plant to produce high quality plastic containers and closures was built at the Kosamba site, and glass production received a new state-of-the-art and sustainable furnace technology. This is in line with the company's formula G growth strategy.
“With our outstanding portfolio in pharma and healthcare solutions, Gerresheimer is contributing to the health and well-being of millions of patients worldwide. India is one of the strongest growing country within the Emerging Markets and a core market of large global pharma companies”, CEO Dietmar Siemssen said. "Our new facilities in India are another important step to serve global pharma customers locally as a one stop shop – with the highest quality and availability."
Gerresheimer follows a clear roadmap for further global capacity increases alongside its holistic capital allocation process. The capacity increase in India is part of Gerresheimer’s investment program to sharpen the company’s growth and return profile. Over the previous two years, the company invested a double digit million Euro amount into new furnaces in Kosamba with the latest glass melting technology.
The new state of the art furnace is equipped with newest production machines also having most sensitive inspection equipment following the Gerresheimer molded glass production standards. With this technology, the company will substantially enhance its product quality. New lines for glass injection vials as well as solid plastic dosages, closures and security systems have also been ramped up.
Further enhancing Gerresheimer’s local production and sales footprint in Emerging Markets is part of the company’s regional expansion plans. With that, Gerresheimer is well positioned for being global partner for pharma solutions and platforms.
Contact Investor Relations
16.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1352895|
|End of News||DGAP News Service|